#1 Clinical Trials Search in Europe

Angiotensin Ii Receptor Blockers (Arbs), Combinations

This article discusses the use of Angiotensin II Receptor Blockers (ARBs) combinations in clinical trials for the treatment of IgA Nephropathy. The focus is on a long-term safety study that includes ARBs as part of the supportive care regimen for patients with this kidney condition. The trial aims to evaluate the safety and efficacy of a new drug called iptacopan while maintaining patients on stable doses of ACE inhibitors or ARBs.

Table of Contents

What are Angiotensin II Receptor Blockers (ARBs) Combinations?

Angiotensin II Receptor Blockers (ARBs) Combinations are a group of medications used to treat various cardiovascular and kidney-related conditions. These drugs work by blocking the effects of a hormone called angiotensin II, which can cause blood vessels to narrow and blood pressure to rise[1].

ARBs are often combined with other medications to enhance their effectiveness in treating certain conditions. These combinations may include diuretics (water pills) or calcium channel blockers, which work together to lower blood pressure and improve overall cardiovascular health[1].

Medical Uses of ARBs Combinations

ARBs Combinations are primarily used to treat the following conditions:

  • Hypertension (High Blood Pressure): ARBs help relax blood vessels, making it easier for the heart to pump blood throughout the body[1].
  • Heart Failure: By reducing the workload on the heart, ARBs can help improve heart function in patients with heart failure[1].
  • Chronic Kidney Disease (CKD): ARBs can help protect the kidneys from further damage in patients with CKD, particularly those with conditions like IgA nephropathy[1].
  • Diabetic Nephropathy: In patients with diabetes, ARBs can help slow down the progression of kidney damage[1].

How ARBs Combinations are Administered

ARBs Combinations are typically administered in the following way:

  • Route: These medications are usually taken orally in the form of tablets or capsules[1].
  • Frequency: Depending on the specific combination and your doctor’s instructions, you may need to take the medication once or twice daily[1].
  • Duration: ARBs Combinations are often prescribed for long-term use to manage chronic conditions. In the clinical trial mentioned, the maximum treatment period was 96 months (8 years)[1].

Current Clinical Trials and Research

ARBs Combinations are being studied in various clinical trials to further understand their benefits and potential new applications. One such trial is investigating the use of ARBs in combination with a drug called iptacopan for treating IgA nephropathy, a kidney disease[1].

Key points about this clinical trial include:

  • It’s a long-term safety study for adults with IgA nephropathy[1].
  • Participants must be on a stable dose of ACE inhibitors (ACEi) or ARBs as part of their supportive care regimen[1].
  • The study aims to evaluate the long-term safety and effectiveness of iptacopan when used alongside ARBs or ACEi[1].

Important Considerations for Patients

If you’re prescribed ARBs Combinations, keep the following in mind:

  1. Regular Monitoring: Your doctor will likely want to monitor your kidney function and blood pressure regularly. In the clinical trial, participants needed to have an eGFR (estimated glomerular filtration rate) of at least 20 mL/min/1.73m2, which is a measure of kidney function[1].
  2. Potential Side Effects: Like all medications, ARBs can have side effects. Common ones include dizziness, headache, and elevated potassium levels[1].
  3. Drug Interactions: ARBs can interact with other medications. Always inform your healthcare provider about all medications you’re taking[1].
  4. Pregnancy and Breastfeeding: ARBs are typically not recommended during pregnancy or while breastfeeding. Discuss with your doctor if you’re pregnant, planning to become pregnant, or breastfeeding[1].
  5. Adherence to Treatment: It’s important to take ARBs Combinations as prescribed, even if you feel well. These medications help manage chronic conditions and their effectiveness relies on consistent use[1].
Aspect Details
Study Type Phase IIIb trial – Phase III and Phase IV (Integrated)
Main Objective Evaluate long-term safety and tolerability of iptacopan
Secondary Objective Characterize clinical benefit (efficacy) of iptacopan
Key Inclusion Criteria Adults with IgA nephropathy, eGFR ≥ 20 mL/min/1.73m2, stable dose of ACEi or ARB
Key Exclusion Criteria Severe urinary obstruction, recent acute kidney injury, rapidly progressive glomerulonephritis
Primary Endpoints Safety and tolerability (AEs/SAEs, safety laboratory parameters, vital signs)
Secondary Endpoints Annualized total eGFR slope, change in eGFR, changes in UPCR and UACR
Treatment Duration Up to 96 weeks
ARBs Role Part of supportive care regimen, administered as stable dose

FAQ

  • What is the main purpose of the clinical trial involving ARBs combinations? The main purpose of the clinical trial is to evaluate the long-term safety and tolerability of a new drug called iptacopan in adult patients with primary IgA nephropathy. ARBs combinations are part of the supportive care regimen that patients continue to receive during the study.
  • Who is eligible to participate in this clinical trial? Eligible participants are adults with primary IgA nephropathy who have completed a previous Novartis-sponsored iptacopan study. They must have an eGFR of 20 mL/min/1.73m2 or higher and be on a stable dose of ACE inhibitors or ARBs as part of their supportive care.
  • What is the duration of treatment in this clinical trial? The maximum treatment period mentioned in the trial information is 96 weeks, which is approximately 2 years.
  • Are there any specific vaccination requirements for participants? Yes, participants should have up-to-date vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae infections, as per local regulations.
  • What are some of the exclusion criteria for this trial? Some exclusion criteria include severe urinary obstruction, acute kidney injury within 4 weeks prior to the study, rapidly progressive glomerulonephritis, and recent use of certain immunosuppressive or immunomodulatory agents.

Ongoing Clinical Trials on Angiotensin Ii Receptor Blockers (Arbs), Combinations

  • Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Germany Hungary +7

Glossary

  • IgA Nephropathy: A kidney disease where antibodies called IgA build up in the kidneys, causing inflammation and damage to kidney tissues.
  • Angiotensin II Receptor Blockers (ARBs): A class of medications that help relax blood vessels, lowering blood pressure and potentially protecting kidney function in certain kidney diseases.
  • eGFR: Estimated Glomerular Filtration Rate, a measure of how well the kidneys are filtering waste from the blood.
  • ACE inhibitors: Angiotensin-Converting Enzyme inhibitors, another class of medications that, like ARBs, help lower blood pressure and protect kidney function.
  • Iptacopan: The investigational drug being studied in this clinical trial for the treatment of IgA nephropathy.
  • KDIGO: Kidney Disease: Improving Global Outcomes, an organization that provides clinical practice guidelines for kidney disease management.
  • Acute Kidney Injury (AKI): A sudden episode of kidney failure or kidney damage that happens within a few hours or days.
  • Rapidly Progressive Glomerulonephritis (RPGN): A severe form of kidney inflammation that can lead to rapid loss of kidney function.

References

  1. http://clinicaltrials.eu/trial/long-term-safety-study-of-iptacopan-for-adults-with-iga-nephropathy-after-completing-a-previous-study-including-ace-inhibitors-and-arbs-drug-combination/